Navigation Links
Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board
Date:11/26/2014

SAN JOSE, Calif., Nov. 26, 2014 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the addition of Steven Opal, M.D., an internationally recognized key opinion leader in the areas of pneumonia and sepsis, to the Company's scientific advisory board.

Founder and Chief Executive Officer, Vu Truong, Ph.D., stated, "We believe Dr. Opal's extensive experience investigating bacterial toxins and key mechanisms involved in the establishment of severe bacterial infections will be instrumental to the future success of Aridis Pharmaceuticals.  We are honored to add this talented medical professional to our Scientific Advisory Board."

Dr. Opal is a Professor of Medicine in the Infectious Disease Division of Alpert Medical School of Brown University and Chief of the Division of Infectious Diseases at Memorial Hospital of Rhode Island.  He has led numerous worldwide, multi-center clinical trials and has served on several data safety monitoring boards. Dr. Opal has authored more than 230 peer-reviewed research articles and edited several academic research journals as well as three textbooks on infectious diseases, endotoxin-mediated diseases, and septic shock. He received his infectious disease training at Walter Reed Army Medical Center, his medical training at Albany Medical College and his bachelor's at Cornell University.

Dr. Opal commented, "I look forward to lending my expertise to help guide and accelerate the advancement of Aridis' promising pipeline of novel anti-infective therapies.  It is exciting to join Aridis' world-class team at this pivotal stage in the company's development."

About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX® and pharmaceutical formulation technologies to produce novel infectious disease focused therapies. Aridis' product pipeline includes AR-301 anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AR-101 anti-Pseudomonas aeruginosa LPS human monoclonal antibody; Panaecin™, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; Aerucin™, a broadly reactive monoclonal antibody against Pseudomonas aeruginosa initially being developed to treat acute pneumonia; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of AR-301, AR-101, Panaecin™, Aerucin™, AR-401, AR-201, Aridis' proprietary formulation and delivery technologies, about Aridis' strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis' expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis' research and clinical studies and its ability to obtain additional financing. These forward-looking statements represent Aridis' judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com
(212) 375-2664

Amy Wheeler (media)
awheeler@tiberend.com
(212) 827-0020

 

 

 


'/>"/>
SOURCE Aridis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2018)... Ga. (PRWEB) , ... September 01, 2018 , ... ... Group, Inc. ( Shaw ) focuses on the company’s continued efforts to “Create ... contribute to healthier environments and preservation of natural resources. , “2017 was ...
(Date:8/31/2018)... , ... August 31, 2018 , ... ... Government to acquire, such as medications for cancer, mental health and required blood ... used to treat Respiratory Distress Syndroms (RDS) in premature babies and can be ...
(Date:8/31/2018)... ... , ... The summertime sweat that many people dread is a year-round reality ... hyperhidrosis. In Grand Rapids , Dr. Brad Bengtson recognized the need for a ... through their shirts for no reason other than the fact that their sweat glands ...
Breaking Medicine Technology:
(Date:9/22/2018)... TAMPA, Fla. (PRWEB) , ... September 21, 2018 , ... ... will speak at the Sept. 25 Hillsborough County Chapter meeting of the Florida Assisted ... Drive in Brandon, Florida. , Dudek’s presentation will provide an overview of the ...
(Date:9/22/2018)... SAN LUIS OBISPO, Calif. (PRWEB) , ... September ... ... many different shapes and sizes. In fact, there are actually 29 different categories ... may qualify. These include charitable or religious organizations (often referred to as a ...
(Date:9/15/2018)... ... September 14, 2018 , ... Last ... full FY 2019 appropriations for Labor, Health and Human Services and Education (LHHS) ... Teen Pregnancy Prevention (TPP) Program, and $286.5 million for the Title X Family ...
(Date:9/12/2018)... Va. (PRWEB) , ... September 12, 2018 , ... De ... For?, **An FDAnews Webinar**, Sept. 25, 2018 — 1:30 p.m. – 3:00 p.m. ET, ... , What applications are being granted by the FDA? , What are the best ...
(Date:9/12/2018)... ... September 13, 2018 , ... Glori Blends will be ... industry leaders. , The expo will include vendors, presentations, panel discussions and a special ... educate attendees on their award winning products and assist customers with the best selection ...
Breaking Medicine News(10 mins):